Utilization management (UM) requirements often delay access to therapies for rare hematologic cancers. In a payer–provider roundtable, experts discussed practical solutions, including guideline-concordant ePAs, expedited pathways, use of real-world evidence, “gold carding” for trusted providers, value-based agreements, and stronger collaboration between payers and providers to ensure timely access to care.